Literature DB >> 9751612

Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells.

A S Coutts1, L C Murphy.   

Abstract

The mitogen-activated protein kinase (MAPK) signal transduction pathway plays an essential role in cell cycle progression and can be activated by many growth factor/mitogen pathways including estrogen. MAPK has also been implicated in ligand-independent activation of estrogen receptor-alpha (ER-alpha). The development of estrogen-independent growth in breast cancer is likely a first step in progression to hormone independence and antiestrogen resistance. We examined MAPK expression and activity in T5-PRF and T5 human breast cancer cells. T5-PRF is an estrogen-nonresponsive cell line developed from T5 cells by chronically depleting the cells of estrogen in long-term culture. MAPK activity measured in vitro was significantly higher (P < 0.05) in T5-PRF compared with T5 cells. Western blot analyses showed increased levels of active dually phosphorylated MAPK in T5-PRF cell extracts compared with T5. The increased activity and expression of MAPK may contribute to the estrogen nonresponsive growth phenotype and ligand-independent activity of ER in T5-PRF cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751612

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Non-transcriptional action of oestradiol and progestin triggers DNA synthesis.

Authors:  G Castoria; M V Barone; M Di Domenico; A Bilancio; D Ametrano; A Migliaccio; F Auricchio
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

Review 2.  Growth factor signalling in endocrine and anti-growth factor resistant breast cancer.

Authors:  R I Nicholson; I R Hutcheson; H E Jones; S E Hiscox; M Giles; K M Taylor; J M W Gee
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

3.  Human chorionic gonadotropin β induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells.

Authors:  Zongwen Li; Lianlian Du; Chunliu Li; Wei Wu
Journal:  J Neurooncol       Date:  2012-12-13       Impact factor: 4.130

Review 4.  Decoding the link between WWOX and p53 in aggressive breast cancer.

Authors:  Suhaib K Abdeen; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2019-05-16       Impact factor: 4.534

5.  The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.

Authors:  Marc A Becker; Yasir H Ibrahim; Xiaojiang Cui; Adrian V Lee; Douglas Yee
Journal:  Mol Endocrinol       Date:  2011-02-03

Review 6.  p27 deregulation in breast cancer: prognostic significance and implications for therapy.

Authors:  A Alkarain; R Jordan; J Slingerland
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 7.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

8.  Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.

Authors:  Yiyun Zhang; Huiping Zhao; Szilard Asztalos; Michael Chisamore; Yasmin Sitabkhan; Debra A Tonetti
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

9.  Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma.

Authors:  Ioannis Pozios; Thomas Knösel; Yue Zhao; Gerald Assmann; Iraklis Pozios; Mario H Müller; Christiane J Bruns; Martin E Kreis; Hendrik Seeliger
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-25       Impact factor: 4.553

10.  Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.

Authors:  Marion T Weigel; Zara Ghazoui; Anita Dunbier; Sunil Pancholi; Mitch Dowsett; Lesley-Ann Martin
Journal:  Breast Cancer Res       Date:  2012-05-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.